Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

Christian Pfister(Université d'Orléans), Stéphane Culine(Hôpital Saint-Louis), Brigitte Laguerre(Centre Eugène Marquis), Valentin Harter, Aude Fléchon(Centre Léon Bérard), Gwénaëlle Gravis(Institut Paoli-Calmettes), Nicolas Mottet, M. Soulié(Hôpital Rangueil), Yves Allory(Hôpital Foch), Laurent Guy, Florence Joly(Centre François Baclesse)
European Urology
August 28, 2020
10.1016/j.eururo.2020.08.024
Cited by 246

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Historical Climatology In Europe – The State Of The Art
|Climatic Change|2005|656
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
|Journal of Clinical Oncology|2021|530